Topical Tofacitinib for Atopic Dermatitis – Outcomes from Randomized Phase 3 Clinical Trial: First Approval

Background: The Janus kinase (JAK) enzyme plays a crucial role in the pathophysiology of atopic dermatitis (AD). The United States Food and Drug Administration (USFDA) has recently granted approval for three JAK inhibitors intended for AD treatment. These comprise topical Ruxolitinib, oral Abrocitin...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Alok R. Chaturvedi, Hemant G. Zaveri, Dhaval V. Patel, Tof-O in AD Trial Investigators
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wolters Kluwer Medknow Publications 2026-01-01
Edice:	Indian Journal of Dermatology
Témata:	atopic dermatitis easi eczema jak inhibitor phase 3 clinical trial tofacitinib
On-line přístup:	https://journals.lww.com/10.4103/ijd.ijd_197_24
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!